Study of XL999 in Adults With Solid Tumors

This study has been completed.

First Received: February 23, 2005 Last Updated: October 20, 2008 History of Changes

Sponsored by:	Exelixis
Information provided by:	Exelixis
ClinicalTrials.gov Identifier:	NCT00104117

Purpose

The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.

Condition	Intervention	Phase
Cancer	Drug: XL999	Phase I

MedlinePlus related topics: Cancer

Drug Information available for: XL 999

Study Type:	Interventional
Study Design:	Treatment, Open Label, Safety Study
Official Title:	A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
Radiotherapy within 4 weeks of the start of treatment
Subjects with known brain metastasis
Uncontrolled medical disorder such as infection or cardiovascular disease
Subjects known to be HIV positive
Pregnant or breastfeeding women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00104117

Locations

United States, Ohio
Case Western Reserve University
Cleveland, Ohio, United States, 44106
United States, Texas
Cancer Therapy and Research Center
San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Exelixis

More Information

No publications provided

Study ID Numbers:	XL999-001
Study First Received:	February 23, 2005
Last Updated:	October 20, 2008
ClinicalTrials.gov Identifier:	NCT00104117 History of Changes
Health Authority:	United States: Food and Drug Administration

ClinicalTrials.gov processed this record on May 07, 2009